Five9 Inc. (NASDAQ:FIVN) is one of the most undervalued technology stocks to buy according to analysts. On September 30, Five9 announced significant changes to its Board of Directors. The company appointed Sudhakar Ramakrishna to the Board of Directors, with his tenure officially beginning on September 26. Simultaneously, the company announced the retirement of Lead Independent Director David Welsh, who concluded over 14 years of service to the Board on the same date. Sudhakar Ramakrishna brings ~25 years ...

投资策略 - 在股市不确定性增加时，价值投资与成长投资的混合策略GARP（合理价格成长）更具优势[1][3] - GARP策略通过PEG比率（市盈增长比率）筛选兼具低估属性和可持续增长潜力的股票[5][6] - PEG比率低于1表明股票同时具备低估和未来增长潜力，例如P/E为10且长期增长率15%时PEG为0 66[6] 筛选标准 - 入选股票需满足PEG和P/E比率低于行业中位数、Zacks评级1-2级（强买/买）、市值超10亿美元[8] - 其他条件包括20日平均交易量超5万股、4周内F1盈利预期修正涨幅超5%、价值评分≤B级[8][9] 推荐标的 - **武田制药（TAK）**：专注胃肠病、罕见病等领域的生物制药公司，核心产品包括Entyvio等，Zacks评级1级，PEG低估且长期增长率达35%[10][11] - **Five9（FIVN）**：提供云端智能客服平台，支持全渠道交互，Zacks评级2级，历史增长率19 3%[12][13] - **LATAM航空（LTM）**：覆盖151个目的地的拉美航司，Zacks评级1级，预期增长率14 8%[13][14] - **瑞穗金融（MFG）**：全球综合性金融服务集团，业务涵盖银行、信托等，Zacks评级2级，预期增长率15 9%[15][16]